{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"3.2","value":"3.1"},{"groupId":"OG001","lowerLimit":"3.0","upperLimit":"3.8","value":"3.1"},{"comment":"The upper bound of the TTP 90% confidence interval was not reached due to insufficient events at the time of analysis.","groupId":"OG002","lowerLimit":"1.2","upperLimit":"NA","value":"4.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"TTP based on Kaplan-Meier method is defined as the time from registration to progression disease (PD), or censored at date of last disease evaluation for those without progression reported. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG000","title":"[Dose Level II] Pembrolizumab + Trebananib (Colorectal)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG001","title":"[Dose Level II] Pembrolizumab + Trebananib (Ovarian)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG002","title":"[Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)"}],"paramType":"MEDIAN","populationDescription":"The analysis population will include patients enrolled in the dose escalation and dose expansion portions of the trial. Per protocol, the dose escalation and dose expansion data may be combined for patients with the same cancer type who received the same treatment doses.","reportingStatus":"POSTED","timeFrame":"Median follow-up was 29.3 months (range 0.9 - 42.0 months).","title":"Median Time To Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Months"}